Is vktx a good buy

**Viking Therapeutics (VKTX) does not appear to be a strong buy at this time**. Here's why:

1. **Financial Performance Concerns**: The company has reported a negative year-over-year revenue growth rate of -15.73% and a negative net income growth rate of -1.53% as of June 30, 2024. These figures indicate that the company is not growing as expected financially.

2. **Net Profit Margin**: The net profit margin for VKTX is -$610.97 million as of June 30, 2024. A negative net profit margin suggests that the company is currently unprofitable, which is a red flag for investors.

3. **Technical Indicators**: The stock's RSI is at 52.15, which is close to the oversold threshold of 30, suggesting that the stock may be undervalued but also indicating a lack of positive momentum.

4. **Support and Resistance Levels**: The current support level is at $55.69, and the resistance level is at $57.6. The stock is trading close to its support level, which could indicate a lack of upward momentum.

Given these points, it is advisable to exercise caution and consider these financial and technical indicators before making an investment decision in VKTX.